Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 2
2008 8
2009 3
2010 5
2011 7
2012 5
2013 3
2014 3
2015 2
2016 3
2017 8
2018 4
2019 9
2020 10
2021 13
2022 10
2023 5
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

97 results

Results by year

Filters applied: . Clear all
Page 1
Qualitative evaluation of motives for acceptance or refusal of early palliative care in patients included in early-phase clinical trials in a French comprehensive cancer center: the PALPHA study.
Lochmann M, Girodet M, Despax J, Baudry V, Duranti J, Mastroianni B, Vanacker H, Vinceneux A, Brahmi M, Renard O, Verlingue L, Amini-Adle M, Swalduz A, Gautier J, Ducimetière F, Anota A, Cassier PA, Chvetzoff G, Christophe V. Lochmann M, et al. Among authors: cassier pa. Support Care Cancer. 2024 May 15;32(6):353. doi: 10.1007/s00520-024-08535-x. Support Care Cancer. 2024. PMID: 38748187
Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study.
González-Martín A, Chung HC, Saada-Bouzid E, Yanez E, Senellart H, Cassier PA, Basu B, Corr BR, Girda E, Dutcus C, Okpara CE, Ghori R, Jin F, Groisberg R, Lwin Z. González-Martín A, et al. Among authors: cassier pa. Gynecol Oncol. 2024 May 7;186:182-190. doi: 10.1016/j.ygyno.2024.04.011. Online ahead of print. Gynecol Oncol. 2024. PMID: 38718741
NF-κB subunits RelA and c-Rel selectively control CD4+ T cell function in multiple sclerosis and cancer.
Lalle G, Lautraite R, Bouherrou K, Plaschka M, Pignata A, Voisin A, Twardowski J, Perrin-Niquet M, Stéphan P, Durget S, Tonon L, Ardin M, Degletagne C, Viari A, Belgarbi Dutron L, Davoust N, Postler TS, Zhao J, Caux C, Caramel J, Dalle S, Cassier PA, Klein U, Schmidt-Supprian M, Liblau R, Ghosh S, Grinberg-Bleyer Y. Lalle G, et al. Among authors: cassier pa. J Exp Med. 2024 Jun 3;221(6):e20231348. doi: 10.1084/jem.20231348. Epub 2024 Apr 2. J Exp Med. 2024. PMID: 38563819
The NF-κB RelA transcription factor is not required for CD8+ T-cell function in acute viral infection and cancer.
Voisin A, Plaschka M, Perrin-Niquet M, Twardowski J, Boutemine I, Eluard B, Lalle G, Stéphan P, Bouherrou K, Tonon L, Pommier R, Ferrari A, Klein U, Wencker M, Baud V, Cassier PA, Grinberg-Bleyer Y. Voisin A, et al. Among authors: cassier pa. Front Immunol. 2024 Mar 5;15:1379777. doi: 10.3389/fimmu.2024.1379777. eCollection 2024. Front Immunol. 2024. PMID: 38504985 Free PMC article.
Xevinapant Combined with Pembrolizumab in Patients with Advanced, Pretreated, Colorectal and Pancreatic Cancer: Results of the Phase Ib/II CATRIPCA Trial.
Voisin A, Terret C, Schiffler C, Bidaux AS, Vanacker H, Perrin-Niquet M, Barbery M, Vinceneux A, Eberst L, Stéphan P, Garin G, Spaggiari D, Pérol D, Grinberg-Bleyer Y, Cassier PA. Voisin A, et al. Among authors: cassier pa. Clin Cancer Res. 2024 May 15;30(10):2111-2120. doi: 10.1158/1078-0432.CCR-23-2893. Clin Cancer Res. 2024. PMID: 38502104 Clinical Trial.
The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers.
Voissière A, Gomez-Roca C, Chabaud S, Rodriguez C, Nkodia A, Berthet J, Montane L, Bidaux AS, Treilleux I, Eberst L, Terret C, Korakis I, Garin G, Pérol D, Delord JP, Caux C, Dubois B, Ménétrier-Caux C, Bendriss-Vermare N, Cassier PA. Voissière A, et al. Among authors: cassier pa. Sci Transl Med. 2024 Jan 24;16(731):eadd1834. doi: 10.1126/scitranslmed.add1834. Epub 2024 Jan 24. Sci Transl Med. 2024. PMID: 38266104
A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies.
Lin CC, Garralda E, Schöffski P, Hong DS, Siu LL, Martin M, Maur M, Hui R, Soo RA, Chiu J, Zhang T, Ma B, Kyi C, Tan DS, Cassier PA, Sarantopoulos J, Weickhardt A, Carvajal RD, Spratlin J, Esaki T, Rolland F, Akerley W, Deschler-Baier B, Rispoli L, Samant TS, Chowdhury NR, Gusenleitner D, Kwak EL, Askoxylakis V, De Braud F. Lin CC, et al. Among authors: cassier pa. Oncoimmunology. 2023 Dec 20;13(1):2290787. doi: 10.1080/2162402X.2023.2290787. eCollection 2024. Oncoimmunology. 2023. PMID: 38170160 Free PMC article. Clinical Trial.
Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study.
Subbiah V, Hu MI, Mansfield AS, Taylor MH, Schuler M, Zhu VW, Hadoux J, Curigliano G, Wirth L, Gainor JF, Alonso G, Adkins D, Godbert Y, Ahn MJ, Cassier PA, Cho BC, Lin CC, Zalutskaya A, Barata T, Trask P, Scalori A, Bordogna W, Heinzmann S, Brose MS. Subbiah V, et al. Among authors: cassier pa. Thyroid. 2024 Jan;34(1):26-40. doi: 10.1089/thy.2023.0363. Thyroid. 2024. PMID: 38009200
Netrin-1 blockade inhibits tumour growth and EMT features in endometrial cancer.
Cassier PA, Navaridas R, Bellina M, Rama N, Ducarouge B, Hernandez-Vargas H, Delord JP, Lengrand J, Paradisi A, Fattet L, Garin G, Gheit H, Dalban C, Pastushenko I, Neves D, Jelin R, Gadot N, Braissand N, Léon S, Degletagne C, Matias-Guiu X, Devouassoux-Shisheboran M, Mery-Lamarche E, Allard J, Zindy E, Decaestecker C, Salmon I, Perol D, Dolcet X, Ray-Coquard I, Blanpain C, Bernet A, Mehlen P. Cassier PA, et al. Nature. 2023 Aug;620(7973):409-416. doi: 10.1038/s41586-023-06367-z. Epub 2023 Aug 2. Nature. 2023. PMID: 37532934 Free PMC article. Clinical Trial.
Phase Ib/II trial of tipapkinogene sovacivec, a therapeutic human papillomavirus16-vaccine, in combination with avelumab in patients with advanced human papillomavirus16-positive cancers.
Borcoman E, Lalanne A, Delord JP, Cassier PA, Rolland F, Salas S, Limacher JM, Capitain O, Lantz O, Ekwegbara C, Jeannot E, Cyrta J, Tran-Perennou C, Castel-Ajgal Z, Marret G, Piaggio E, Brandely M, Tavernaro A, Makhloufi H, Bendjama K, Le Tourneau C. Borcoman E, et al. Among authors: cassier pa. Eur J Cancer. 2023 Sep;191:112981. doi: 10.1016/j.ejca.2023.112981. Epub 2023 Jul 11. Eur J Cancer. 2023. PMID: 37506588 Clinical Trial.
97 results